A comparison of the effects of Buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis.
Twelve patients receiving Buserelin and seven patients receiving danazol for treatment of endometriosis were studied to assess the effect of medication on plasma lipoproteins. Danazol significantly lowered plasma HDL-C levels at 6 months of treatment. Total plasma cholesterol was elevated at 6 months of therapy in the Buserelin group. No effect by either drug on plasma triglycerides was seen.
D000328:Adult; D002064:Buserelin / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003613:Danazol / Q000627:therapeutic use*; D004715:Endometriosis / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D011245:Pregnadienes / Q000627:therapeutic use*
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008074:Lipoproteins; D011245:Pregnadienes; D002784:Cholesterol; D003613:Danazol; D002064:Buserelin